TVIX NEWS! 7.37 Daily 2X VIX ST ETN Velocityshares (TVIX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Daily 2X VIX ST ETN Velocityshares (TVIX) 7.37 $TVIX

Dow Correction: Why You Shouldn't Panic Over Market Volatility
Dan Caplinger, The Motley Fool - Motley Fool - Wed Mar 26, 3:30PM CDT
On Wednesday, the Dow Jones Industrials lost almost 100 points, finishing near the day's lows as investors worried about a variety of factors that could hurt the market's future prospects. That range of issues runs from the threat of war in...

A Perfect Trade for Increased Volatility: TVIX
at The Street - Mon Mar 24, 1:02PM CDT
If volatility is getting set to spike dramatically higher, then this trading vehicle could be a great way to play it.

The Dow Gets Complacent Again, but is the Russia-Ukraine Conflict Really Over?
Dan Caplinger, The Motley Fool - Motley Fool - Mon Mar 17, 11:30AM CDT
After the weekend's referendum on Crimea's rejoining Russia went much as expected, but without any huge escalation in the conflict, investors celebrated by sending the Dow Jones Industrials up nearly 190 points, or 1.2%, as of 12:30 p.m. EDT. At...

Russia Sends Dow Down 200+; Is Ukraine a Black-Swan Event?
Dan Caplinger, The Motley Fool - Motley Fool - Mon Mar 03, 11:00AM CST
Russia's aggressive moves in the Crimean region of Ukraine sparked massive sell-offs around the world on Monday, with Russian stocks losing more than 10% of their value and European markets getting hit especially hard. Even the Dow Jones Industrials...

Volatility ETFs Crash as Market Fears Drop - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 1:00PM CST
Thanks to declining worries about the market, volatility ETNs have lost all of their 2014 momentum.

Investors Have Declared the Dow Pullback Over
Dan Caplinger, The Motley Fool - Motley Fool - Tue Feb 11, 11:30AM CST
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. The Dow Jones Industrials are celebrating Tuesday, rising...

Volatility ETFs Skyrocket on Broad Market Weakness - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Mon Feb 03, 9:00AM CST
Inside the incredible run in the volatility ETF market over the past ten days.

Is Market Volatility Back for 2014?
Dan Caplinger, The Motley Fool - Motley Fool - Sun Jan 26, 10:30AM CST
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. The S&P 500 fell 2.6%, with a 38-point plunge in the...

Why Texas Industries, Open Text, and VelocityShares Daily 2x VIX Soared Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Jan 24, 7:01PM CST
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Yesterday's drop in the stock market turned into a rout...

Will Stock-Market Volatility Come Back in 2014?
Dan Caplinger, The Motley Fool - Motley Fool - Thu Dec 26, 10:15PM CST
The year 2013 has been an exceptionally strong one for stock market investors, who scored big gains on their portfolios in a broad-based advance in the fifth year of the current bull market. One of the most surprising things about 2013 was that those...

2013: The Year Volatility Died
Dan Caplinger, The Motley Fool - Motley Fool - Sun Dec 08, 5:55PM CST
The stock market in 2013 gave investors almost exactly what they wanted: sizable returns without any major correction along the way. But what drove such strong results, and can 2014 give investors another chance at such favorable conditions? In the...

What Correction? 1 Key Sign Investors Remain Complacent
Dan Caplinger, The Motley Fool - Motley Fool - Thu Dec 05, 1:06PM CST
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. The losing streak for the U.S. stock market could reach five...

The Two Month VIX Cycle
Chad Karnes - ETFG - Fri Nov 15, 7:37PM CST
Buying the VIX is a great way to hedge your portfolio, if you can get the timing right. Luckily, the VIX has provided us some excellent technical clues that we can combine with the uncertainty from Washington to come up with some great VIX trades.

The Soaring Dow Has Made This Smart Strategy Cheaper
Dan Caplinger, The Motley Fool - Motley Fool - Fri Nov 08, 11:31AM CST
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. As has happened so many times during the bull market since...

The Dow Shows No Fear
Dan Caplinger, The Motley Fool - Motley Fool - Wed Oct 16, 1:00PM CDT
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Investors often assume that when there's fear around the...

American Default Worries are Great News for These ETFs - ETF News And Commentary
Eric Dutram - ZACKS - Wed Oct 16, 9:00AM CDT
Altohugh many stocks and ETFs are down on Washington D.C. issues, these ETFs have been strong performers.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Kulicke & Soffa Announces Conference Call for Fiscal Results

Updated Category News Views 122

Kulicke & Soffa Schedules Conference Call Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC), a leading name in semiconductor assembly technology, has announced a conference call to discuss its third fiscal quarter financial results and business outlook. The call is set for a future date, highlighting the company's commitment to transparency and communication with its...

Continue Reading
ARMOUR Residential REIT Launches Major Stock Offering for Growth

Updated Category News Views 162

ARMOUR Residential REIT Enters Public Stock Offering ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) has officially announced an underwritten public offering of 18,500,000 shares of common stock. The company is poised to grant underwriters an additional option to purchase up to 2,775,000 shares, making this a significant move for ARMOUR as it aims to enhance its...

Continue Reading
Celebrate Mother's Day with a Unique Brunch at Cannon + Belle

Updated Category News Views 195

Cannon + Belle Offers a Memorable Mother's Day Brunch Cannon + Belle at Hilton Austin is excited to announce an elevated Mother's Day brunch that promises to create unforgettable memories. This year, the restaurant will be hosting a special brunch event aimed at honoring mothers and all they do. With an impressive menu curated by the talented Chef Gereamy Cater, guests...

Continue Reading
Figma's Shares Surge in IPO But Valuation Remains a Concern

Updated Category News Views 244

Figma's Impressive IPO Performance Figma Inc. (NYSE: FIG) has captured significant investor attention following its explosive debut in the stock market. After launching its initial public offering, the company's shares skyrocketed by over 250%, marking a remarkable milestone for the firm. The stock began trading at a price of $33 per share, leading to approximately $1.2...

Continue Reading
Journey Medical Corporation's Emrosi Launch for Rosacea Relief

Updated Category News Views 215

Journey Medical Corporation Introduces Emrosi for Rosacea Treatment Journey Medical Corporation, a key player in the dermatological pharmaceutical industry, has recently launched Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), designed for the effective treatment of rosacea. The product, featuring a unique formulation of 10 mg immediate release and...

Continue Reading